Skip to main content
. Author manuscript; available in PMC: 2017 Oct 17.
Published in final edited form as: J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):217–228. doi: 10.1515/jbcpp-2015-0118

Figure 5.

Figure 5

Mice lacking CB1 receptors did not display tetrad effects following CP47,497 (30 mg/kg) administration.

Age-matched CB1 (+/+) and (−/−) mice were treated with either vehicle or CP47,497 (30 mg/kg). CP47,497-treated CB1 (+/+) mice displayed (A) catalepsy, (B) antinociception, (C) hypothermia, and locomotor immobility as indicated by decreases in (D) distance traveled and (E) time spent immobile. In contrast, CP47,497-treated CB1 (−/−) mice did not differ from vehicle-treated CB1 (+/+) and (−/−) mice, implying CB1 mediation of these effects. Values represent means±SEM. ****p < 0.0001 vs. vehicle-treated mice.